论文部分内容阅读
目的研究上皮性卵巢癌组织中FOXO3a、Bim mRNA及p-AKT、FOXO3a、Bim蛋白的表达情况及与临床病理学特征之间的关系。方法用Real time-PCR法检测FOXO3a、Bim在25例正常卵巢上皮组织(正常组)、21例良性卵巢肿瘤组织(良性组)及43例上皮性卵巢癌组织(恶性组)中的mRNA表达情况;用免疫组化法检测3种组织中的p-AKT、FOXO3a、Bim蛋白表达情况。结果 1FOXO3a在正常组、良性组、恶性组中mRNA表达水平无统计学差异(P>0.05);Bim在正常组、良性组、恶性组中mRNA表达水平依次降低(P<0.05)。2p-AKT在正常组、良性组、恶性组中蛋白表达水平依次升高(P<0.05);FOXO3a、Bim在正常组、良性组、恶性组中蛋白表达水平依次降低(P<0.05)。3FOXO3a与p-AKT蛋白表达水平呈负相关(r=-0.584,P<0.05);FOXO3a与Bim蛋白表达水平呈正相关(r=0.437,P<0.05)。4FOXO3a蛋白的表达水平与肿瘤病理分级相关,而与患者年龄、肿瘤大小、淋巴结转移、临床分期等临床病理特征之间均无明显相关性(P>0.05)。结论 p-AKT、FOXO3a、Bim可能与上皮性卵巢癌的发生发展有关。
Objective To investigate the expression of FOXO3a, Bim mRNA, p-AKT, FOXO3a and Bim protein in epithelial ovarian cancer and their relationship with clinicopathological features. Methods The mRNA expression of FOXO3a and Bim in 25 cases of normal ovarian epithelial tissue (normal group), 21 cases of benign ovarian tumor (benign group) and 43 cases of epithelial ovarian cancer (malignant group) were detected by Real time-PCR Immunohistochemistry was used to detect the expression of p-AKT, FOXO3a and Bim in three tissues. Results There was no significant difference in mRNA expression level of 1FOXO3a between normal group, benign group and malignant group (P> 0.05). The mRNA level of Bim in normal group, benign group and malignant group decreased in turn (P <0.05). The protein expression levels of 2p-AKT in normal group, benign group and malignant group were increased in turn (P <0.05). The protein expression levels of FOXO3a and Bim in normal group, benign group and malignant group were decreased in turn (P <0.05). There was a negative correlation between the expression of 3-FOXO3a and p-AKT (r = -0.584, P <0.05). The FOXO3a and Bim protein levels were positively correlated (r = 0.437, P <0.05). The expression level of 4FOXO3a protein was correlated with tumor grade, but not with clinical pathological features such as age, tumor size, lymph node metastasis and clinical stage (P> 0.05). Conclusion p-AKT, FOXO3a, Bim may be related to the occurrence and development of epithelial ovarian cancer.